Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Enovis (NYSE: ENOV) reported third-quarter 2025 results for the period ended October 3, 2025, with net sales of $549 million, up 9% reported and 7% organic year‑over‑year. Recon sales rose 12% reported (9% organic); P&R sales grew 6% reported (4% organic). The company reported a GAAP net loss of $571 million driven by a $548 million non‑cash goodwill impairment, and adjusted EBITDA was $95 million (17.3% margin) with adjusted EPS of $0.75. Enovis completed the October divestiture of its Diabetic Footcare business for up to $60 million and raised full‑year 2025 adjusted EBITDA and adjusted EPS guidance, with revenue guidance narrowed to $2.24–2.27 billion.
Enovis (NYSE: ENOV) announced it will release Third Quarter 2025 financial results and host a conference call and live webcast on Thursday, November 6, 2025 at 8:30 a.m. ET, with an earnings press release issued earlier that morning.
A presentation and live webcast will be available on the Enovis Investors website. Executives will also participate in investor conferences: a UBS Global Healthcare fireside chat on Monday, November 9 at 2:45 p.m. ET and a Jefferies London Healthcare fireside chat on Tuesday, November 18 at 3:30 p.m. GMT (10:30 a.m. ET). Live audio webcasts and replays will be posted under Investors > Events and Presentations.
Enovis (NYSE: ENOV) completed the sale of its Dr. Comfort footcare diabetic shoe business to Promus Equity Partners for up to $60 million in cash, comprising an $45 million upfront payment and up to $15 million in milestone payments.
The company said the divestiture sharpens focus on its Prevention & Recovery franchise, aims to expand margins, enhance profitability, and accelerate debt reduction. Enovis will discuss strategic details on its Q3 results call on Nov 6, 2025 at 8:30 am ET. Promus is a multi-family asset manager with approximately $2.7 billion under management. Citizens Capital Markets & Advisory and Tucker Ellis LLP advised Enovis.
Enovis Corporation (NYSE:ENOV), a medical technology growth company, has announced a schedule change for its presentation at the Baird 2025 Global Healthcare Conference. The company will now present on Wednesday, September 10th, 2025 at 2:35 p.m. ET. Investors can access both the live audio webcast and replay through the Events and Presentations section under the Investors tab on Enovis' website.
Enovis Corporation (NYSE: ENOV), a medical technology growth company, has announced its upcoming participation in three major investor conferences:
- Canaccord Genuity 45th Annual Growth Conference on August 13th at 8:30 a.m. ET
- Wells Fargo Healthcare Conference on September 3rd at 2:15 p.m. ET
- Baird 2025 Global Healthcare Conference on September 10th at 3:10 p.m. ET
Live audio webcasts and replays will be accessible through the Investors section of the company's website under Events and Presentations.
Enovis (NYSE:ENOV) reported strong Q2 2025 financial results with net sales of $565 million, representing a 7% reported growth and 5% organic growth year-over-year. The company's Reconstructive segment grew 11% on a reported basis, while Prevention & Recovery (P&R) increased 5%.
Despite positive sales growth, Enovis recorded a net loss of $37 million (6.5% of sales) and adjusted EBITDA of $97 million (17.2% of sales). The company updated its 2025 guidance, raising revenue expectations to $2.245-2.275 billion and adjusted EPS guidance to $3.05-3.20.
Enovis Corporation (NYSE: ENOV), a medical technology growth company, will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. ET. The company will release its earnings report earlier that morning.
Investors can access the live webcast through Enovis' website investor section, and those wishing to participate in the call can dial (833) 685-0901. A presentation and replay of the call will be available on the company's website following the event.
Enovis Corporation (NYSE: ENOV) reported strong Q1 2025 financial results with net sales of $559 million, representing an 8% growth on a reported basis and 9% on a comparable basis. The company's Reconstructive segment showed impressive growth of 11% year-over-year, while P&R segment grew 5%. However, Enovis reported a net loss from continuing operations of $56 million (-$0.98 per share).
The company achieved an adjusted EBITDA of $99 million (17.7% of sales), marking a 160 basis point improvement from the previous year. Enovis updated its 2025 guidance, raising revenue expectations to $2.22-2.25 billion but lowering adjusted EBITDA forecast to $385-395 million due to $20 million in tariff-related impact. The company also announced the appointment of Damien McDonald as CEO, effective May 12th, 2025.
Enovis (NYSE: ENOV) has announced it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time. The company will release its earnings press release earlier that morning. A presentation and webcast will be accessible through the 'Investors' section of Enovis' website.
Investors can participate by dialing (833) 335-0887 with Access Code: 482081, or preregister through a provided link. A replay of the call will be made available on the company's website later that day.